Se Gwang Jang

Se Gwang Jang

Auto-generated profile, based on publicly available information

Se Gwang Jang

The Rheumatism Research Center, The Catholic University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Immune Network
Verified
Journal Article
Open access
PDF file
SHSeung-Min Hong
Seung-Min Hong
JLJaeseon Lee
Jaeseon Lee
SJSe Gwang Jang
Se Gwang Jang
JLJennifer Jooha Lee
Jennifer Jooha Lee
Mi-La ChoMi-La Cho
Mi-La Cho
SPSung-Hwan Park
Sung-Hwan Park
Hong SM, et al. Immune Netw. 2020 Oct;20(5):e39. https://doi.org/10.4110/in.2020.20.e39

31 December 2023 in Korean Journal of Clinical Laboratory Science
Verified
Journal Article
Open access
PDF file
SJSe Gwang Jang
Se Gwang Jang
Se Gwang JANG. Korean J Clin Lab Sci. 2023;55:306-13. https://doi.org/10.15324/kjcls.2023.55.4.306

19 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
SJSe Gwang Jang
Se Gwang Jang
JLJaeseon Lee
Jaeseon Lee
SHSeung-Min Hong
Seung-Min Hong
YSYoung-Seok Song
Young-Seok Song
MKMin Jun Kim
Min Jun Kim
SPSung-Hwan Park
Sung-Hwan Park
Background. Autoantibody production against endogenous cellular components is pathogenic feature of systemic lupus erythematosus (SLE). Follicular helper T (TFH) cells aid in B cell differentiation into autoantibody-producing plasma cells (PCs). The IL-6 and IL-21 cytokine-mediated STAT3 signaling are crucial for the differentiation to TFH cells. Niclosamide is an anti-helminthic drug used to treat parasitic infections but also exhibits a therapeutic effect on autoimmune diseases due to its potential immune regulatory effects. In this study, we examined whether Niclosamide treatment could relieve lupus-like autoimmunity by modulating the differentiation of TFH cells in two murine models of lupus.Methods. 10-week-old MRL/lpr mice were orally administered with 100 mg/kg of Niclosamide or with 0.5% methylcellulose (MC, vehicle) daily for 7 weeks. TLR7 agonist, resiquimod was topically applied to an ear of 8-week-old C57BL/6 mice 3 times a week for 5 weeks. And they were orally administered with 100 mg/kg of Niclosamide or with 0.5% MC daily for 5 weeks. Every mouse was analyzed for lupus nephritis, proteinuria, autoantibodies, immune complex, immune cell subsets at the time of the euthanization.Results. Niclosamide treatment greatly improved proteinuria, anti-dsDNA antibody levels, immunoglobulin subclass titers, histology of lupus nephritis, and C3 deposition in MRL/lpr and R848-induced mice. In addition, Niclosamide inhibited the proportion of TFH cells and PCs in the spleens of these animals, and effectively suppressed differentiation of TFH-like cells and expression of associated genes in vitro.Conclusions. Niclosamide exerted therapeutic effects on murine lupus models by suppressing TFH cells and plasma cells through STAT3 inhibition.

30 September 2024 in Korean Journal of Clinical Laboratory Science
Verified
Journal Article
Open access
PDF file
SJSe Gwang Jang
Se Gwang Jang
Se Gwang JANG. Korean J Clin Lab Sci. 2024;56:207-16. https://doi.org/10.15324/kjcls.2024.56.3.207